- Home
- AMGN vs QCOM Comparison
AMGN vs QCOM Comparison
Compare AMGN & QCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- QCOM
- Stock Information
- Founded
- AMGN 1980
- QCOM 1985
- Country
- AMGN United States
- QCOM United States
- Employees
- AMGN N/A
- QCOM N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- QCOM Radio And Television Broadcasting And Communications Equipment
- Sector
- AMGN Health Care
- QCOM Technology
- Exchange
- AMGN Nasdaq
- QCOM Nasdaq
- Market Cap
- AMGN 156.2B
- QCOM 173.2B
- IPO Year
- AMGN N/A
- QCOM 1991
- Fundamental
- Price
- AMGN $306.95
- QCOM $152.72
- Analyst Decision
- AMGN Buy
- QCOM Buy
- Analyst Count
- AMGN 21
- QCOM 28
- Target Price
- AMGN $323.26
- QCOM $203.96
- AVG Volume (30 Days)
- AMGN 3.0M
- QCOM 7.2M
- Earning Date
- AMGN 05-01-2025
- QCOM 04-30-2025
- Dividend Yield
- AMGN 3.10%
- QCOM 2.23%
- EPS Growth
- AMGN N/A
- QCOM 35.10
- EPS
- AMGN 7.56
- QCOM 9.33
- Revenue
- AMGN $33,424,000,000.00
- QCOM $40,696,000,000.00
- Revenue This Year
- AMGN $7.36
- QCOM $13.65
- Revenue Next Year
- AMGN $2.18
- QCOM $4.56
- P/E Ratio
- AMGN $40.60
- QCOM $16.36
- Revenue Growth
- AMGN 18.57
- QCOM 12.13
- 52 Week Low
- AMGN $253.30
- QCOM $149.43
- 52 Week High
- AMGN $346.85
- QCOM $230.63
- Technical
- Relative Strength Index (RSI)
- AMGN 47.38
- QCOM 39.63
- Support Level
- AMGN $304.29
- QCOM $153.56
- Resistance Level
- AMGN $317.58
- QCOM $161.47
- Average True Range (ATR)
- AMGN 5.64
- QCOM 3.91
- MACD
- AMGN -2.39
- QCOM 0.30
- Stochastic Oscillator
- AMGN 13.44
- QCOM 20.81
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About QCOM QUALCOMM Incorporated
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.